0.7056

3.01% -0.0225

Tenaya Therapeutics Inc (TNYA)

Overview News Price History Option Chain Financials Discussions Forecast

Tenaya Therapeutics Inc stock is traded at $0.7056, with a volume of 3.93M. It is down -3.01% in the last 24 hours and down -13.56% over the past month. Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.

Previous Close:

$0.7281

Open:

$0.7214

24h Volume:

3.93M

Relative Volume:

1.44

Market Cap:

$159.45M

Revenue:

Net Income/Loss:

$-83.01M

P/E Ratio:

-1.4975

EPS:

-0.4712

Net Cash Flow:

$-64.63M

1W Performance:

-4.23%

1M Performance:

-13.56%

6M Performance:

+11.88%

1Y Performance:

-39.12%

1-Day Range:

$0.68

$0.7275

1-Week Range:

$0.68

$0.7894

52-Week Range:

$0.5316

$2.35

Tenaya Therapeutics Inc Stock (TNYA) Company Profile

Name

Tenaya Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

415-865-2066

Address

171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

TNYA's Discussions on Twitter

Compare TNYA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNYA Tenaya Therapeutics Inc	0.7111	163.26M	0	-83.01M	-64.63M	-0.4712
VRTX Vertex Pharmaceuticals Inc	515.63	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	807.01	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	991.71	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	213.05	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.46	39.31B	5.76B	514.49M	1.10B	4.4813

Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-10-24	Initiated	William Blair	Outperform
Nov-30-23	Initiated	Leerink Partners	Outperform
Jun-15-22	Initiated	H.C. Wainwright	Buy

Tenaya Therapeutics Inc Stock (TNYA) Latest News

05:43 AM

GSA Capital Partners LLP Makes New $1.97 Million Investment in Tenaya Therapeutics, Inc. $TNYA - MarketBeat

05:43 AM

Aug 16, 2026

Tenaya Therapeutics (TNYA) Q2 2026 Earnings: EPS Misses by 186.94% as Clinical-Stage Pipeline Drives Wider-Than-Expected LossEarnings Power Value - dars.gov.et

Aug 16, 2026

Aug 14, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 14, 2026

Transcript : Tenaya Therapeutics, Inc. Presents at Canaccord Genuity's 46th Annual Growth Conference, Aug-11-2026 12 - marketscreener.com

Aug 14, 2026

Tenaya Therapeutics (TNYA) Institutional Ownership 2026 - MarketBeat

Aug 14, 2026

Aug 11, 2026

Tenaya Therapeutics at Canaccord Genuity conference: q4 catalysts loom By Investing.com - Investing.com Canada

Aug 11, 2026

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Aug 11, 2026

Aug 10, 2026

Renaissance Technologies LLC Increases Stock Holdings in Tenaya Therapeutics, Inc. $TNYA - MarketBeat

Aug 10, 2026

HC Wainwright Has Positive Outlook of TNYA FY2026 Earnings - MarketBeat

Aug 10, 2026

Aug 07, 2026

Q3 Earnings Forecast for TNYA Issued By HC Wainwright - MarketBeat

Aug 07, 2026

Aug 06, 2026

H.C. Wainwright Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $3 - Moomoo

Aug 06, 2026

William Blair Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating - Moomoo

Aug 06, 2026

Aug 05, 2026

Tenaya Therapeutics (NASDAQ:TNYA) Issues Quarterly Earnings Results - MarketBeat

Aug 05, 2026

Tenaya Therapeutics (TNYA) Gains 5.81% as Biotech Stock Holds Above Critical $0.74 SupportZero Gamma Level - dars.gov.et

Aug 05, 2026

Tenaya Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com

Aug 05, 2026

Tenaya Therapeutics Q2 net loss widens on impairment charge - TradingView

Aug 05, 2026

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times

Aug 05, 2026

Tenaya Therapeutics (TNYA) Jumps 5.8% to $0.78 as It Tests Key Resistance at $0.82Watchlist Stock Ideas - dars.gov.et

Aug 05, 2026

Tenaya Therapeutics (TNYA) to Post Earnings on Wednesday - MarketBeat

Aug 05, 2026

Aug 04, 2026

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times

Aug 04, 2026

Tenaya CFO Eric Hyllengren to Speak at Boston Conference - Stock Titan

Aug 04, 2026

Aug 01, 2026

Tenaya Therapeutics (TNYA) Slips to $0.74 as Key Support at $0.70 Comes into FocusButterfly Setup - dars.gov.et

Aug 01, 2026

Jul 27, 2026